We invite you to engage in an interactive nintely minute roundtable led by EverythingALS consortia of Pharma partners, sensor companies, neurologists, data scientists, regulators and patients to help advance the discovery and implementation of ALS digital biomarkers in clinical trials through our collaborative efforts.
Joining our participatory roundtable, you will be the first to learn about our latest study results on ALS digital biomarkers as well as have the opportunity to hear why major pharmaceutical companies have joined the consortium to partner in EverythingALS research, which will be expanded to include analyzing data from wearables and smartphones.
As always, we approach each roundtable to encourage out-of-the-box thinking, and to kick it off, we have an exciting agenda! Take a look below.
This is an invite only event.
Hosts & Speakers
Agenda
Monday March 4th, 2024
12:30 PM - 2 PM ET I 9:30 AM - 11:00 AM PT
5 minutes
15 minutes
15 minutes
15 minutes
30 minutes
Welcome and Consortia Updates
Indu Navar
Keynote : Person living with ALS
Martha and Paul Beach will share with us the impact of ALS on family, and support and shared-decisions
Grant Opportunities with the ALS Research Programs
Sarah N. Fontaine
Will present the congressionally directed medical research programs, U.S. Army Medical Research and Development Command
EverythingALS Vision 2030 AI Research Hub
Merit Cudkowicz and Ernest Fraenkel
Vision: 2030: a First-of-its-Kind AI Research Hub in ALS
Panel: 'What It Takes'
Michelle Crouthamel, Lyle Ostrow, Ernest Fraenkel, David Shulman and Sarah N. Fontaine
"What It Takes": Making Digital Endpoints and Outcomes Foundational to Powered Studies in 2024 - Perspectives from Researchers, Clinicians, Industry and People with ALS
Agenda
Monday September 9th, 2024
12:00 NOON - 1:30 PM ET I 9:00 AM - 10:30 AM PT
Welcome, Updates, and Announcements: EverythingALS App and the Consortia Portal
We will share the latest updates and release of EverythingALS App and the Consortia portal, and how these tools are supporting the ALS community.
Welcoming new consortia members Regeneron and Neuvivo.
Indu Navar, Founder & CEO, EverythingALS
Comments from the new Consortia members
Ari Azhir, CEO & Founder, Neuvivo
Matthew Wipperman, Associate Director, Digital Medicine, Regeneron
15 minutes
10 minutes
15 minutes
40 minutes
05 minutes
Keynote and Q&A: "How to identify high performing Teams"
John will delve into the essential characteristics and behaviors that define high performing teams by drawing upon real-world examples.
John Hudacek, pALS
Refinement of workstreams
Potential projects, sign-ups, and process for setting meeting cadences
EverythingALS team and Consortia
Closing Remarks
Indu Navar
THANK YOU - END OPEN SESSION
CONSORTIA MEMBERS' BREAKOUT
12:45 - 1:30 PM ET